Php236 - Quality of Evidence on the Cost-Effectiveness of Drugs Proposed for the Inclusion in the Russian Vital and Essential Drugs List in 2014-2017

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1130
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn286 - Incremental Cost-Effectiveness Ratio for the Antineoplastic Drugs Approved and Rejected for the Vital and Essential Drugs List in 2017 in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Inclusion of Ipragliflozin Into the Vital and Essential Drugs List: Budget Impact Analysis

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
2019English

Strategies -Based on Evidence- To Rationalize the High Cost Drugs National List in the Dominican Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis

PharmacoEconomics - Open
Health PolicyPharmacology
2018English

The World Health Organization's Model List of Essential Drugs Among Nurses and Pharmacists in Zambia

Journal of Managed Care Pharmacy
2000English

Evaluation of Antihypertensive Drugs on the Reimbursement List for the Delisting Policy in Korea

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Designing the Free Drugs List in Nepal

MDM Policy and Practice
Health PolicyPublic HealthOccupational HealthEnvironmental
2017English

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014 .

2014English

Inclusion of TB Diagnostics on the WHO Essential Diagnostics List

International Journal of Tuberculosis and Lung Disease
MedicinePulmonaryInfectious DiseasesRespiratory Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy